How many recent candidates the COVID-19 vaccine demonstrated satisfactory level three clinical trial results. Now the next unique challenge that must be solved is how this vaccine can be distributed around the world safely.
Some of the COVID-19 vaccine candidates are known to require storage in extreme cold temperatures so that their contents are not easily damaged. Vaccine COVID-19 from Pfizer-BioNTech, for example, it takes a temperature of minus 70 degrees Celsius.
Faced with this, dry ice or the iceberg is now needed to solve the potential problem of vaccine distribution to countries or regions where facilities may be inadequate.
The Compressed Gas Association said dry ice production in the United States (US) and Canada could reach up to 30,000 tons a day. It is predicted that it will take less than five percent of it to support cold storage of the COVID-19 vaccine just for these areas.
“Meanwhile in the world who is ready? Nothing,” commented Dr Jarbas Barbosa of the Pan American Health Organization commenting on the challenge of sending vaccines abroad as quoted by CNN, Sunday (22/11/2020).
CEO of BioNTech, Ugur Sahin, admitted that his party will continue to strive to develop vaccines that are more resistant to temperature. However, it is estimated that this will take time, at least until mid-2021.
“We are working on a formula that might allow the vaccine to be stored at room temperature,” said Sahin.